We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.
Obtaining a DEL from Health Canada is one of the more complex regulatory processes a drug company will face in Canada. That’s why QSS guides manufacturers, OTC brands, and international importers through every stage, from initial assessment and application preparation through to annual maintenance and ongoing compliance.
A Drug Establishment Licence is the legal authorization Health Canada issues to companies conducting regulated drug activities in Canada. That includes fabrication, packaging, labelling, testing, importation, distribution, and wholesale. Without a valid DEL covering your specific activities, those operations are not permitted under Canadian law.
For international companies importing or distributing drugs in Canada, the DEL requirement is broader than it might first appear. Every foreign building involved in fabrication, packaging, or testing of imported drugs must be listed on your licence and must demonstrate GMP compliance through Health Canada inspection or a recognized regulatory authority. Getting that structure right upfront, and keeping it current as your operations evolve, is what keeps your supply chain running.
The DEL process is also time-sensitive. Health Canada’s standard review timeline runs approximately 250 calendar days for the inspection and licence issuance phase alone. Companies that enter the process underprepared, with documentation gaps or a QMS that doesn’t reflect their actual operations, can face extended timelines, requests for additional information, or findings that require remediation before a licence is issued. Getting ahead of those issues is a business decision, not just a compliance one.
Before you file, you need to know exactly what you’re filing for. We assess your business model, activities, and distribution structure to determine the specific DEL categories and building designations that apply to your operations. This includes reviewing whether your activities fall under fabrication, packaging/labelling, testing, importation, distribution, or wholesale, and identifying whether any foreign buildings need to be listed on your licence. The output is a clear picture of what your DEL application needs to cover and what your QMS needs to demonstrate before submission.
A GMP (Good Manufacturing Practice) gap audit is the most reliable way to understand where your operations stand before Health Canada conducts its own review. We conduct a mock inspection against Health Canada’s GMP expectations under Division 2 of the Food and Drug Regulations, covering your Quality Management System, facilities, equipment, personnel, documentation, laboratory practices, data integrity, and supplier controls. You receive a structured written report with prioritized findings and remediation recommendations, so you go into the application process knowing what needs to be addressed.
We complete and file your Drug Establishment Licence application (Form FRM-0033) on your behalf, ensuring it’s accurate, complete, and aligned with Health Canada’s current expectations. This includes preparing your QMS summary, documenting building information for domestic and foreign sites, compiling the product list, assembling GMP compliance evidence, and coordinating the Quality Assurance Person (QAP) designation. We verify every section before submission to reduce the likelihood of deficiency notices, and we manage the fee structure to ensure the application is properly scoped.
If your gap audit surfaces issues that need to be addressed before submission or inspection, we support the remediation process directly. This includes developing or updating Standard Operating Procedures (SOPs), supporting your QMS buildout, assisting with CAPA (Corrective and Preventive Action) implementation, and preparing the documentation package Health Canada will review during inspection. For international companies setting up Canadian operations, we also support facility setup guidance and operational procedure development aligned with Canadian GMP standards.
Your DEL authorizes your operations, but your products also need to be registered with Health Canada before they can be sold in Canada. Once your DEL is in place, we can support Drug Identification Number (DIN) applications and Abbreviated or New Drug Submissions (ANDS/NDS) in parallel. See our dedicated DIN and ANDS/NDS service pages for full details on those services.
If you’re a Canadian importer, your DEL must list all foreign buildings involved in the fabrication, packaging, labelling, or testing of drugs you import. We support the annexation process for foreign sites: assessing GMP compliance documentation, coordinating with foreign manufacturers on the required evidence package, and managing the submission to Health Canada. We also support foreign site management on an ongoing basis, including updates triggered by facility changes, ownership changes, or regulatory authority inspection outcomes.
A DEL is not a one-time filing. Annual renewal submissions are due by April 1st each year (Form C.01A.008), and any material changes to your activities, facilities, product categories, or QAP designations require an amendment (Form C.01A.005) before those changes take effect. We manage your annual renewal cycle so it doesn’t catch you unprepared, and we advise on whether a proposed operational change requires formal pre-approval or just notification to Health Canada. Ongoing licence compliance is part of what we support, not just the initial application.
The latest on DEL requirements, Health Canada GMP expectations, and drug regulatory updates in Canada.
Yes, if you are a Canadian importer bringing drugs into Canada for distribution or sale, you are required to hold a DEL that covers the importation activity. Your licence must also list all foreign buildings involved in fabricating, packaging, labelling, or testing those drugs. Health Canada will verify GMP compliance for each listed foreign site as part of the licensing process.
Health Canada’s standard review and inspection timeline is approximately 250 calendar days from the time of a complete application. That clock doesn’t start until your application is accepted as complete. Gaps in documentation, missing QAP information, or an incomplete QMS summary can all add significant time before you even reach the review phase. Well-prepared applications move faster. We typically recommend building 12 to 18 months into your planning horizon if you’re establishing operations that require a new DEL.
A QAP (Quality Assurance Person, sometimes called a Qualified Person in other jurisdictions) is required for every DEL. They are responsible for GMP compliance at each building where licensed activities take place. Health Canada requires that your QAP have relevant education, typically a degree in pharmacy, chemistry, microbiology, or a related science, plus at least two to five years of quality assurance experience in the pharmaceutical industry. You must designate a QAP in your application, and their credentials are subject to Health Canada review.
Your Canadian importer will need a DEL covering the importation activity, and your US facility will need to be listed as a foreign building on that DEL. Health Canada will assess GMP compliance for your US facility. This can be done through a Health Canada inspection or, in many cases, through recognition of an inspection conducted by the FDA or another accepted regulatory authority. We support both the Canadian importer’s application and the foreign site documentation package, and we can advise on whether your US facility’s existing regulatory standing qualifies for recognition.
Health Canada will issue a notice requesting additional information or clarification if your application is not complete or if the QMS documentation doesn’t meet their requirements. Significant deficiencies can pause the review clock or require remediation before the inspection can proceed. The best way to avoid this is a thorough pre-submission review, which is exactly what our gap audit and application preparation process is designed to do. If you receive a deficiency notice, we can help you prepare the response.
Health Canada’s base application fee for 2025 is $4,660 CAD. Additional fees apply for each activity category your licence covers, and foreign building assessments carry their own fee schedules, ranging from approximately $1,088 CAD for a foreign building to $49,558 CAD for domestic sterile dosage fabricators. Annual renewal fees also apply. Our consulting fees depend on the scope of your application, the number of buildings involved, and whether you need GMP remediation support alongside the filing. We review scope and options in an initial consultation.
Yes. Amendments are required whenever you add or change buildings, activities, drug categories, or QAP designations. We manage the full amendment process: assessing whether a change requires formal pre-approval or notification, preparing the required documentation, and tracking the submission through Health Canada review. Annual renewals (due April 1st) are also something we can take off your plate entirely.
Drug Identification Number (DIN) Application
Once your DEL is in place, your drug products need a DIN before they can be sold in Canada. Our dedicated DIN service covers the full application process.
ANDS and NDS Registration
For companies filing Abbreviated or New Drug Submissions with Health Canada alongside their DEL.
Psychedelics Compliance
For companies operating in Canada’s regulated psychedelics space, we support licensing, compliance, and Health Canada regulatory requirements.
Talk to a specialist about your situation. Whether you’re starting a new application, managing a foreign site, or working through a compliance gap, we can help you map out the right path forward.